Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vinod Rustgi

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 9, 2008
Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis CDavid R Nelson, Vinod Rustgi, Vijayan Balan, et al.
Therapeutic Advances in Gastroenterology|September 2, 2015
The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial)Fred Poordad, Vinod Rustgi, Robert S Brown, et al.
The New England Journal of Medicine|January 20, 2012
Preliminary study of two antiviral agents for hepatitis C genotype 1Anna S Lok, David F Gardiner, Eric Lawitz, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 17, 2015
Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patientsGregory T Everson, Karen D Sims, Paul J Thuluvath, et al.
Gastroenterology|November 5, 2013
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infectionGregory T Everson, Karen D Sims, Maribel Rodriguez-Torres, et al.
Annals of Hepatology|October 15, 2016
Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infectionMaribel Rodriguez-Torres, Eric Lawitz, Bienvenido Yangco, et al.
The New England Journal of Medicine|April 12, 2014
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosisKris V Kowdley, Stuart C Gordon, K Rajender Reddy, et al.
Journal of Hepatology|July 28, 2014
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infectionAndrew J Muir, Sanjeev Arora, Gregory Everson, et al.
Archives of Internal Medicine Research|May 2, 2024
African Americans Possessed High Prevalence of Comorbidities and Frequent Abdominal Symptoms, and Comprised A Disproportionate Share of Covid-19 Mortality among 9,873 Us- Hospitalized Patients Early in the PandemicHassan Ashktorab, Antonio Pizuorno, Lakshmi Gayathri Chirumamilla, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 9, 2008
Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis CDavid R Nelson, Vinod Rustgi, Vijayan Balan, et al.
Therapeutic Advances in Gastroenterology|September 2, 2015
The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial)Fred Poordad, Vinod Rustgi, Robert S Brown, et al.
The New England Journal of Medicine|January 20, 2012
Preliminary study of two antiviral agents for hepatitis C genotype 1Anna S Lok, David F Gardiner, Eric Lawitz, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 17, 2015
Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patientsGregory T Everson, Karen D Sims, Paul J Thuluvath, et al.
Gastroenterology|November 5, 2013
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infectionGregory T Everson, Karen D Sims, Maribel Rodriguez-Torres, et al.
Annals of Hepatology|October 15, 2016
Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infectionMaribel Rodriguez-Torres, Eric Lawitz, Bienvenido Yangco, et al.
The New England Journal of Medicine|April 12, 2014
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosisKris V Kowdley, Stuart C Gordon, K Rajender Reddy, et al.
Journal of Hepatology|July 28, 2014
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infectionAndrew J Muir, Sanjeev Arora, Gregory Everson, et al.
Archives of Internal Medicine Research|May 2, 2024
African Americans Possessed High Prevalence of Comorbidities and Frequent Abdominal Symptoms, and Comprised A Disproportionate Share of Covid-19 Mortality among 9,873 Us- Hospitalized Patients Early in the PandemicHassan Ashktorab, Antonio Pizuorno, Lakshmi Gayathri Chirumamilla, et al.
Pageof 5